ATE551052T1 - Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz - Google Patents

Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz

Info

Publication number
ATE551052T1
ATE551052T1 AT05810560T AT05810560T ATE551052T1 AT E551052 T1 ATE551052 T1 AT E551052T1 AT 05810560 T AT05810560 T AT 05810560T AT 05810560 T AT05810560 T AT 05810560T AT E551052 T1 ATE551052 T1 AT E551052T1
Authority
AT
Austria
Prior art keywords
diastolic
heart failure
prevent
treat
renin inhibitors
Prior art date
Application number
AT05810560T
Other languages
German (de)
English (en)
Inventor
David Feldman
Friedrich Luft
Dominik Mueller
Randy Webb
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE551052(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE551052T1 publication Critical patent/ATE551052T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT05810560T 2004-10-08 2005-10-06 Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz ATE551052T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61720204P 2004-10-08 2004-10-08
US66789905P 2005-04-01 2005-04-01
PCT/US2005/035914 WO2006041974A1 (en) 2004-10-08 2005-10-06 Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure

Publications (1)

Publication Number Publication Date
ATE551052T1 true ATE551052T1 (de) 2012-04-15

Family

ID=35789048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810560T ATE551052T1 (de) 2004-10-08 2005-10-06 Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz

Country Status (15)

Country Link
US (2) US20080085914A1 (enExample)
EP (2) EP2248520A3 (enExample)
JP (1) JP2008515903A (enExample)
KR (2) KR20070101843A (enExample)
CN (1) CN101102755B (enExample)
AT (1) ATE551052T1 (enExample)
AU (2) AU2005294318A1 (enExample)
BR (1) BRPI0516128A (enExample)
CA (1) CA2580862A1 (enExample)
ES (1) ES2384637T3 (enExample)
MX (1) MX2007004020A (enExample)
PL (1) PL1799199T3 (enExample)
PT (1) PT1799199E (enExample)
RU (1) RU2407523C2 (enExample)
WO (1) WO2006041974A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
KR20090127174A (ko) 2007-03-27 2009-12-09 칼피스가부시키가이샤 심부전 예방제
AR066168A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
JP2010540548A (ja) * 2007-09-28 2010-12-24 ノバルティス アーゲー アリスキレンとバルサルタンの医薬組み合わせ剤
MX2011007779A (es) * 2009-01-28 2011-08-12 Novartis Ag Formulaciones galenicas de compuestos organicos.
EP2340820A1 (en) * 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2216020A1 (en) * 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
WO2010089105A2 (en) * 2009-02-05 2010-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Moisture-activated granulation process
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
US20110268797A1 (en) * 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
ES2142789T3 (es) 1989-06-14 2000-05-01 Smithkline Beecham Corp Acidos imidazolil-alquenoicos.
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
RU2147875C1 (ru) * 1990-05-11 2000-04-27 Пфайзер Инк. Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
TW226375B (enExample) 1991-10-24 1994-07-11 American Home Prod
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
DE602004022704D1 (de) * 2003-11-26 2009-10-01 Novartis Ag 4-phenylpiperidinderivate als renininhibitoren
CN1882528A (zh) * 2003-11-26 2006-12-20 诺瓦提斯公司 有机化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
KR20070101843A (ko) 2007-10-17
EP1799199B1 (en) 2012-03-28
JP2008515903A (ja) 2008-05-15
CN101102755A (zh) 2008-01-09
US20080085914A1 (en) 2008-04-10
BRPI0516128A (pt) 2008-08-26
MX2007004020A (es) 2007-05-24
AU2010200833A1 (en) 2010-04-01
PL1799199T3 (pl) 2012-09-28
RU2007116863A (ru) 2008-11-20
CN101102755B (zh) 2013-01-02
EP1799199A1 (en) 2007-06-27
US20130196977A1 (en) 2013-08-01
EP2248520A3 (en) 2010-11-17
EP2248520A2 (en) 2010-11-10
KR20130048281A (ko) 2013-05-09
RU2407523C2 (ru) 2010-12-27
AU2005294318A1 (en) 2006-04-20
CA2580862A1 (en) 2006-04-20
AU2010200833B2 (en) 2011-07-14
ES2384637T3 (es) 2012-07-10
WO2006041974A1 (en) 2006-04-20
PT1799199E (pt) 2012-07-03

Similar Documents

Publication Publication Date Title
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
MY170728A (en) Treatment for diabetes in patients inappropriate for metformin therapy
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
EP1756106A4 (en) CYCLOHEXYLALANINE DERIVATIVES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
UA100111C2 (ru) Лечение диабета типа 2 комбинацией ингибитора dpiv и метформина или тиазолидиндиона
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
WO2009017863A3 (en) Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
MX2007004001A (es) Metodo para el tratamiento de poliquistosis renal.
ATE551052T1 (de) Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
EA200870093A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения ожирения
EP1905452A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
WO2007019153A3 (en) Methods for treating hypertension
WO2004098599A3 (en) Proton pump inhibitors for the treatment of lower abdominal disorders
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus